9188 results for 'fabp3 t face'

In the dynamic landscape of biomedical research, organoids have emerged as a groundbreaking tool, offering three-dimensional (3D) models that mimic the complex architecture and functionality of hu

Protocole ELISA contre les anticorps hétérophiles en clinique et labo Un résultat Elisa qui ne colle pas au tableau clinique évoque d’abord une interférence par anticorps hétérophiles, surtout sur un

This article breaks down the glycoprotein Granulocyte-macrophage colony-stimulating factor (GM-CSF) detailing its structure, function and therapeutic uses. It also describes its role in imm

By Eoin Mac Réamoinn Toll-like receptors (TLRs) are renowned for their fundamental roles in innate sensing and initiating inflammatory responses. TLRs acco

Notch signalling pathway review The Notch signalling pathway is a highly conserved intercellular signalling pathway that regulates various cellular processes. The Notch receptor is a transmem

In the intricate tapestry of the immune system, macrophages play a pivotal role, orchestrating a wide range of biological responses that protect the body against pathogens, remove cellular debris,

What is VEGF? Vascular Endothelial Growth Factors (VEGFs) are a group of homodimeric polypeptides, and are master regulators of vascular development, maintenance and a

Quick Facts About MurlentamabWhat is Murlentamab?Murlentamab is a novel monoclonal antibody designed to target CD47, a "don’t eat me" signal that helps cancer cells evade the immune syst

Quick Facts About TomaralimabWhat is Tomaralimab?Tomaralimab is an anti-CD47 monoclonal antibody designed to enhance immune system recognition of cancer cells by blocking the "don't eat

Quick Facts About VesencumabWhat is Vesencumab?Vesencumab is an experimental monoclonal antibody designed to target CD47, a key regulator of immune evasion in cancer cells.How Does Vesen

Quick Facts About FletikumabWhat is Fletikumab?Fletikumab is an investigational monoclonal antibody targeting CD47, a key immune checkpoint that enables cancer cells to evade immune dest

By Rachel Bleach, PhD Student, RCSI By the age of 79 years, 1 in 14 women will develop breast cancer (Global Burden of Disease Cancer 2017). Beatson reported

Nod-like receptors Nod like receptors (NLRs) are a versatile family of relatively recently discovered intracellular receptors which have a br

What You Need to Know About AmatuximabIs Amatuximab safe?Amatuximab has shown a manageable safety profile in clinical trials, with most side effects being mild to moderate. Severe advers

Quick Facts About IvuxolimabWhat is ivuxolimab?Ivuxolimab is a monoclonal antibody targeting CD47, a "don't eat me" signal that cancer cells exploit to evade immune destruction.How does

Quick Facts About NatalizumabWhat is Natalizumab?Natalizumab is a monoclonal antibody used to treat multiple sclerosis (MS) and Crohn's disease. It works by blocking immune cells from at

Quick Facts About EmapalumabWhat is Emapalumab?Emapalumab is a fully human monoclonal antibody that neutralizes interferon-gamma (IFN-γ). It is the first FDA-approved therapy for primary

Quick Info Section: Key Facts About CevostamabWhat is Cevostamab?Cevostamab is an investigational monoclonal antibody targeting CD47, a cell surface protein that helps cancer cells evade